(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of 432.33% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.12%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.11%.
Humacyte's revenue in 2026 is $2,038,000.On average, 9 Wall Street analysts forecast HUMA's revenue for 2026 to be $5,317,579,656, with the lowest HUMA revenue forecast at $2,399,582,519, and the highest HUMA revenue forecast at $10,404,259,439. On average, 8 Wall Street analysts forecast HUMA's revenue for 2027 to be $20,765,891,209, with the lowest HUMA revenue forecast at $10,878,936,292, and the highest HUMA revenue forecast at $35,713,993,713.
In 2028, HUMA is forecast to generate $76,994,006,463 in revenue, with the lowest revenue forecast at $37,592,275,367 and the highest revenue forecast at $154,352,124,264.